Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?

KOSOVA B., KOSOVA B., AYGÜNEŞ JAFARI D. D., KOSOVA B., KOSOVA B., KOSOVA B.

TURK PSIKIYATRI DERGISI, vol.28, no.2, pp.89-94, 2017 (SSCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.5080/u14883
  • Journal Name: TURK PSIKIYATRI DERGISI
  • Journal Indexes: Social Sciences Citation Index (SSCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.89-94
  • Hacettepe University Affiliated: No

Abstract

Objective: Methylphenidate is the first-choice medication for the Pervasive Developmental Disorders (PDDs), and comorbid Attention Deficit Hyperactivity Disorder (ADHD). But this approach generally results with poor outcomes, and increased adverse effects. It is aimed to investigate the comparison of cases who diagnosed with PDDs and Mild Mental Retardation (MR) and cases with pure ADHD in terms of the clinical response to MPH. Also we aimed to investigate the relations between CES-1 polymorphism gene and the clinical response to MPH.